And the dark horse in that area of ovarian cancer diagnosis is a little-known Australian company, Healthlinx Ltd (ASX: HTX; www.healthlinx.com.au). We know Healthlinx because they are a client of Allen & Caron, the publisher of this blog. Their OvPlex blood test, approved for use in several countries (but not the USA yet), may be the first effective test for ovarian cancer. One of the most common forms of cancer in women, the gold standard of diagnosis is a test called CA125, which has a dismally low ability to diagnose (but it’s the best thing we have so far). If clinical tests to date are any indicator, OvPlex could give new hope to women all over the world, and at a more-than-reasonable price. HTX shares trade only on the Australian Stock Exchange, and are priced at $0.01 with volume of 1.5 million shares per day, and a market cap of about $2.4 million. There is no ADR at this point, but the largest market for ovarian cancer tests is the US, and it is highly likely that HTX will be have a US presence in the near future.
